Development of a Molecular Diagnostic Tool for Endometrial Cancer.

Completed

• Conditions: Endometrium Cancer

• Registration Number: NCT06192017
• Lead Sponsor: MiMARK Diagnostics, S.L.

Brief Summary

WomEC is an in vitro diagnostic test for Endometrial Cancer (EC) based on the detection of the expression level of a combination of 5 proteins in the soluble fraction of a pipelle biopsy specimen. The aim of the study consists in validating WomEC's ELISA test, creating and freezing an algorithm to rule out EC in post-menopausal women with abnormal uterine bleeding (AUB).

Detailed Description

Not available

Study Timeline

• Study Start: 2023-10-18
• Study First Submitted: 2023-12-20
• Study First Submitted QC: 2023-12-20
• Study First Posted: 2024-01-05
• Primary Completion: 2025-07-31
• Study Completion: 2025-07-31
• Status Verified: 2025-08
• Last Update Submitted: 2025-08-21
• Last Update Posted: 2025-08-28

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 1950

Inclusion Criteria

• Post-menopausal women (≥1 year without menstruation) with AUB who present with:

  1. Endometrium > 3mm by transvaginal ultrasound, OR
  2. Endometrium ≤ 3mm who meet at least one of the following criteria:

  i. Persistent symptoms (more than one episode of metrorrhagia) ii. Heterogenous endometrium on transvaginal ultrasonography iii. Risk factors (BMI ≥ 30, use of tamoxifen, hormone replacement therapy (HRT), Lynch syndrome, BRCA mutation.

• Obtaining written informed consent

Exclusion Criteria

• Women with an active pelvic infection.
• Women who have had viral infections with evidence of active and latent disease such as Hepatitis B, Hepatitis C, and HIV infection. Patients who have had Hepatitis C in the past but who have been successfully treated and in whom viral replication has not been observed in the last year will be included.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Regulatory Requirements Study	12 months	Ensure the stability of the samples under defined conditions (pre-analytica) and the analytical validation of the developed WomEC's ELISA test.
Algorithm testing and freeze	12 months	To test and freeze the defined algorithm measured with MiMARK's antibodies to rule out EC in post-menopausal women with AUB.
Algorithm training with Proprietary Antibodies	12 months	Train the current WomEC's algorithms defined in MS by assessing the clinical performance of different EC biomarkers individually and in combination to rule out EC in post- menopausal women with AUB using MiMARK's proprietary antibodies.

Secondary Outcome Measures

Name	Time	Method
Evaluation of the performance of WomEC to determine other prognostic factors of EC.	12 months	Calculate the sensitivity, specificity, accuracy, precision, and clinical validity of WomEC to determine other prognostic factors of EC.
To determine the accuracy of WomEC alone for the diagnosis of EC by pipelle biopsy.	12 months	Test the ability of WomEC to discriminate between EC and non-EC patients.
Evaluation of the performance of different models of WomEC to determine histological subtype.	12 months	Calculate the sensitivity, specificity, accuracy, precision, and clinical validity of WomEC to determine an histological subtype.
Evaluation of the performance of WomEC to diagnose endometrial atypical hyperplasia.	12 months	Calculate the sensitivity, specificity, accuracy, precision, and clinical validity of WomEC to diagnose endometrial atypical hyperplasia.

Trial Locations

Locations (26)

Hospital Universitari Germans Trias i Pujol; 🇪🇸 Badalona, Barcelona, Spain

Hospital Dexeus - Quirón de Barcelona; 🇪🇸 Barcelona, Barcelona, Spain

Hospital Universitario de Igualada; 🇪🇸 Igualada, Barcelona, Spain

Hospital Universitario de la Plana; 🇪🇸 Villarreal, Castellon, Spain

Hospital Clínico de Santiago; 🇪🇸 A Coruña, Galicia, Spain

Hospital Virgen de las Nieves; 🇪🇸 Granada, Granada, Spain

Hospital Clínico Universitario Virgen de la Arrixaca; 🇪🇸 El Palmar, Murcia, Spain

Hospital Universitario de Torrevieja; 🇪🇸 Torrevieja, Alicante, Spain

Hospital Universitari Son Espases; 🇪🇸 Palma de Mallorca, Balearic Islands, Spain

Hospital Universitari Campus Vall d'Hebron; 🇪🇸 Barcelona, Barcelona, Spain

Scroll for more (16 remaining)